Advancing Our Mission Through Clinical Trials
As a leader in neuro-oncology, we believe that patients are partners in progress. We are deeply grateful to the patients, their families, and the medical community who participate in our clinical trials. Your involvement is essential to advancing our understanding of disease and can potentially benefit patients worldwide.
Deciding to participate is a significant choice, as therapies investigated in clinical trials are not yet approved by regulatory agencies like the FDA. While the benefits and risks are not completely known, your participation helps us determine if these new investigational drugs are safe and effective.
If you are interested in learning about our current studies and eligibility requirements, please follow the links below.
Commitment to Research
NeOnc’s technology, consistently validated through extensive research, drives our commitment to developing new formulations and confirming their positive impact on disease. With over a decade of rigorous R&D, we’ve published more than 63 peer-reviewed papers and secured 179 patents globally. The information below highlights our completed research, clinical trials, and ongoing validation studies as we strive to deliver better solutions for Central Nervous System (CNS)-based diseases.
The primary hurdle in effectively treating CNS cancers isn’t just a lack of better drugs; it’s getting therapeutics to the brain without compromising their ability to cure. This critical barrier is the Blood-Brain Barrier (BBB).
The BBB is the brain’s natural defense, blocking large molecules like viruses and neurotoxins. Unfortunately, it also prevents beneficial agents, such as chemotherapeutics, from reaching tumor sites within the brain.
NeOnc has discovered a potential solution to this long-standing problem, actively working to transform pharma-based CNS disease treatment.
